References
1. Nannegari V, Roque S, Rubin DT et al. A review of inflammatory bowel disease in the setting of liver transplantation. Gastroenterology and Hepatology 2014; 10: 626-630 [PMID: 27540334]
2. Kanizaj TF, Mijic M. Inflammatory bowel disease after liver transplanted patients. World J Gastroenterol 2017; 18: 3214-3227 [PMID: 28566881 DOI:10.3748/wjg.v23.i18.3214]
3. Singh S, Loftus EV, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol 2013; 108:1417-1425 [PMID: 23896954 DOI: 10.1038/ajg.2013.163. Epub 2013 Jul 30]
4. Joshi D, Bjarnason I, Belgaumkar A, et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 2013; 33: 53-61 [PMID: 22103794 DOI: 10.111/j.1478-3231.2011.02677]
5. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-1429 [PMID: 16686766 DOI: 10.1111/j.1600-6143.2006. 01333.x]
6. Indriolo A, Ravelli P. Clinical management of inflammatory bowel disease in the organ recipient. World J Gastroenterol 2014; 20:3525-3533. [PMID: 24707135 DOI: 10.3748/wjg.v20.i13.3525
7. Hampton DD, Polenski M and Onken J. Inflammatory bowel disease following solid organ transplantation. Clinical Immunolgy 2008;128:287-293. [PMID: 18708022 DOI:10.1016/j.clim.2008.06.011]
8. Jørgensen KK, Lindström L, Cvancarova M, et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:517-523 [PMID: 23333218 DOI: 10.1016/j.cgh.2012.12.027]
9. Mouchli MA, Singh S, Boardman L, et al. Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflamm Bowel Dis 2018; 24: 1074-1080 [PMID 29522202
10.Navaneethan U, Choudhary M, Venkatesh PG, et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ter 2012;35:1054-1063 [PMID: 22428731 DOI: 10.1111/j.1365-2036.2012.05067. x]
11. Mogl M, Baumgart DC, Fisher A, et al. Immunosuppression following liver Transplantation and the course of inflammatory bowel disease-a case control study.
Z Gastroenterol 2018; 56: 117-127 [PMID:29212098 DOI: 10.1055/s-0043-117183.
624]
12.Riley TR, Schoen RE, Lee RG, et al. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279-282 [PMID: 9040206]
13. Kochlar G, Singh T, Dust H, et al. Impact of the novo and pre-existing inflammatory bowel disease on the outcome of orthotopic liver transplantation. Inflamm Bowel Dis 2016; 22: 1670-1678 [PMID: 27306073 DOI:10.1097/MIB.0000000000000830]
14. Bhat M, Pasini E, Copeland J, et al. Impact of immunosuppression on the metagenomic composition
of the intestinal microbiome: a systems biology Approach to pos-transplant Diabetes. Sci Rep 2017; 31:1-12 [PMID: 28860611 DOI: 10.1038/s41598-017-10471-2]
15. Lv YL, Han FF, Jia YJ, et al. Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? A meta-analysis. Infection and drug resistance 2017;10: 511-519 [PMID: 29276397 DOI: 10.2147/IDR.S149784]
16. Angarone M, Snydman DR. Diagnosis and management of diarrhea in solid-organ transplant recipinets: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 2019; 33: 1-10
17. Pittman ME, Jessurun J, Yantiss RK. Differentiating posttransplant inflammatory bowel disease and other colitides in renal transplant patients. Am J Surg Pathol. 2017; 41:1666-1674.[PMID:28786879.DOI: 10.1097/PAS.0000000000000921]
18. Ecehenique IA, Penugonda S, Sotosor V, et al. Diagnostic yields in solid organ transplant admitted with diarrhea. Clin Infect Dis 2015; 60: 729-737 [PMID: 25371488 DOI: 10.1093/cid/ciu880 ]
19. EL-Nachef N, Terdiman J, Mahadevan U. Anti-tumour necrosis factor therapy for inflammatory bowel disease in the setting of immunosupression for solid organ transplantation. Am J Gastroenterol 2010; 105:1210-1211 [PMID: 20445523] DOI: 10.1038/ajg],
20. Schnitzler F, Friedrich M, Stallhofer J, et al. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. PLoS One 2015; 10: e0135807 [PMID: 26288187 DOI: 10.1371/journal.pone.0135807]
21. Altwegg R, Combes R, Laharie D, et al. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Digestive and Liver Disease 2018; 668-674 DOI: 10.1016/j.dld.2018.02.014
22. Westerouen van Meeteren MJ, Hayee B, Inderson A, et al. Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Meta analysis. J Crohns Colitis. 2017; 11: 1146-1151. [PMID: 28482085 DOI: 10.1093/ecco-jcc/jjx057. Review]
23. Shaikh S, Fitzgerald L, Tischer S. Safety and efficacy of biologic agents for the management of inflammatory bowel disease after liver transplantation. Pharmacotherapy 2017; 37: 1578-1585 [PMID: 27306073 DOI: 10.1002/phar.2036]
24.- M.Martínez-Montiel, Pilar Piedracoba-Cadahia, Carlos Gómez-Gómez, J. Gonzalo. Ustekinumab is effective and safe in the treatment of Crohn’s disease refractory to anti-TNFα in an orthotopic liver transplant patient. Journal of Crohn's and Colitis 2015; 816–817 DOI: 10.1093/ecco-jcc/jjv109).
25. Merchea A, Shahjehan F, Croome KP, et al. colorectal cancer characteristics and outcomes after solid organ transplantation. Journal of Oncology 2019; 2018: 1-8 [PMID 30941176 DOI: 10.1155/2019/5796108]
26. Noone AM, Pfeiffer RM, Dorgan JF, et al. Cancer-attributable mortality among solid organ transplant recipients in The United States: 1987 trough 2014. Cancer 2019; 125: 2647-2655 [PMID 31034602 DOI: 10.10027cncr.32136]
27. Safaeian M, Robbins HA, Berndt SI, et al. Risk of colorectal cancer after solid organ transplantation in the United States. American Journal of Transplantation 2016; 16: 960-967 [PMID 26731613 DOI: 10.1111/ajt13549
28. Singh S, Varayil J, E Loftus EV Jr, et al. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl. 2013; 19:1361–1369 [PMID: 24019127 DOI:10.1002/lt.23741]
29. Rao BB, Lashner B, Kowdley KV. Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflammatory Bowel Dis 2018 24:269-276 [PMID: 29361103 doi: 10.1093/ibd/izx056]
30. Shah SC, Joren R, Castaneda D, et al. High Risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2018; 16: 1106-1113 [PMID: 29378311
DOI: 10.1016/j.cgh.2018.01.023]